Synthesis of 2′-fluoro-5-[11C]-methyl-1-β-d-arabinofuranosyluracil ([11C]-FMAU): A potential nucleoside analog for in vivo study of cellular proliferation with PET

https://doi.org/10.1016/0969-8051(95)00017-RGet rights and content

Abstract

Rapid in vivo catabolism limits the use of currently available radiotracers used in tumor proliferation studies with PET. This is manifested by the need to develop complex mathematical models to interpret kinetic and metabolite data obtained from imaging studies with agents such as carbon-11 labeled thymidine. A potential carbon-11 labeled radiotracer for cellular proliferation, 2′-fluoro-5-([11C]-methyl)-1-β-d-arabinofuranosyluracil (FMAU), has been prepared using a previously described method for preparation of [11dmethyl-thymidine where selective alkylation of a pyrimidyl dianion is accomplished with [11C]methyl iodide at the 5-position of the pyrimidine ring. FMAU shares many in vivo characteristics of thymidine, including cellular transport, phosphorylation by mammalian kinase, and incorporation into DNA. Most importantly, in vivo catabolism of FMAU is limited, potentially yielding simplified kinetic models for determination of cellular proliferation with positron emission tomography.

References (46)

  • M.M. Alauddin et al.

    Synthesis of high specific activity [11C-methyl]-thymidine for in vivo imaging by positron emission tomography

  • M.M. Alauddin et al.

    Synthesis of 2′-fluoro-5-[11C-methyl]-1-β-d-arabinofuranosyluracil ([11C]-FMAU) for use in in vivo imaging by positron emission tomography

  • T.-C. Chou et al.

    Pharmacological disposition and metabolic fate of 2′-fluoro-5-iodo-1-β-d-arabinofuranosyl-cytosine in mice and rats

    Cancer Res.

    (1981)
  • T.-C. Chou et al.

    Synthesis and biological effects of 2′-fluoro-5-ethyl-1-β-d-arabinofuranosyluracil

    Antimicrob. Agents Chemother.

    (1987)
  • J.A. Coderre et al.

    Mechanism of action of 2′,5-difluoro-1-arabinosyluracil

    J. Med. Chem.

    (1983)
  • P.S. Conti et al.

    Potential use of carbon-11 labeled thymidine (TdR) for studying the effect of therapy on prostatic adenocarcinoma in vivo

  • P.S. Conti et al.

    Comparative uptake studies of radiolabeled thymidine in the Dunning R3327H fast-growing and R3327H slow-growing prostate adenocarcinomas in vivo

  • P.S. Conti et al.

    Carbon-11 labeled alpha-aminoisobutyric acid, 2-deoxy-d-glucose and thymidine as potential imaging agents for prostatic and renal malignancies

  • P.S. Conti et al.

    Tumor imaging with positron-emission tomography (PET) and [11C]-thymidine: Determination of radiolabeled thymidine metabolites by high pressure liquid chromatography (HPLC) for kinetic data analysis

    Radiology

    (1989)
  • P.S. Conti et al.

    Analysis of nucleoside metabolism during positron emission tomography (PET) imaging studies of brain tumors with carbon-11 labeled thymidine (TdR)

  • P.S. Conti et al.

    Multiple radiotracers for evaluation of intracranial mass lesions using PET

    J. Nucl. Med.

    (1991)
  • M.P. Fanucchi et al.

    Phase I trial of 1-(2′-deoxy-2′-fluoro-1-β-d-arabinofuranosyl)-5-methyluracil (FMAU)

    Cancer Treat. Rep.

    (1985)
  • A. Feinberg et al.

    2′-Fluoro-5-methyl-1-β-d-arabinosyluracil (FMAU), a potent antiviral agent is metabolized in mice to 2′-fluoro-5-hydroxymethyl-1-β-d-arabinosyluracil and to an FMAU adduct

  • Cited by (127)

    • Tracking Docetaxel-Induced Cellular Proliferation Changes in Prostate Tumor-Bearing Mice with <sup>18</sup>F-FMAU PET

      2023, Academic Radiology
      Citation Excerpt :

      Preliminary pharmacokinetic studies by others and by us have shown that radiolabeled FMAU behaves very similar to thymidine with respect to the rate of cellular uptake, saturability of cellular incorporation, and presence of intracellular metabolite pools. Radioisotopes carried by FMAU are resistant to degradation and are selectively retained in DNA, reflective of tumor cell division (10–12). Currently, several clinical trials (NCT02809690 and NCT02079181) are underway to investigate the utility of 18F-FMAU in diagnosing and characterizing cancers, including prostate cancer, breast cancer, and brain cancer.

    • Microwave-assisted one-pot radiosynthesis of 2'-deoxy-2'-[<sup>18</sup>F]fluoro-5-methyl-1-β-d-arabinofuranosyluracil ([<sup>18</sup>F]-FMAU)

      2012, Nuclear Medicine and Biology
      Citation Excerpt :

      Further clinical investigation of C-11 or F-18 radiolabeled FMAU, in comparison with [18F]-FLT, is warranted, which may ultimately complement the role of [18F]-FLT or other cell proliferation markers currently under development. The radiosynthesis of [11C]-FMAU was first reported in our group [5]. However, the procedure to prepare [11C]-FMAU involves the formation of dilithio compound which makes the production complicated, hard to control, and unreliable.

    • Positron emission tomography imaging of cancer biology: Current status and future prospects

      2011, Seminars in Oncology
      Citation Excerpt :

      Moreover, high physiological uptake of [18F]FLT in bone marrow and liver will pose a problem in the assessment of therapy response of disease involving these organs. FMAU has been developed for cell proliferation imaging with labeling either in the 5-methyl group of the pyrimidine base with 11C or at the 2′-fluoro position of the sugar with 18F.101 Preclinical studies have shown that FMAU retention in tumors and nontumor tissues with rapid cell turnover (eg, marrow and small intestine) reflects incorporation into DNA.102,103

    • Molecular Imaging and Targeted Therapy: Radiopharmaceuticals and Clinical Applications, Second Edition

      2023, Molecular Imaging and Targeted Therapy: Radiopharmaceuticals and Clinical Applications, Second Edition
    View all citing articles on Scopus
    View full text